v3.21.2
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Net sales $ 257,719 $ 204,199
Cost of sales 86,722 66,468
Gross margin 170,997 137,731
Operating expenses:    
Selling, general and administrative 86,175 72,598
Research and development 21,600 16,041
Total operating expenses 107,775 88,639
Operating income 63,222 49,092
Other income (expense) 4,161 (9,753)
Earnings before income taxes 67,383 39,339
Income taxes (benefit) (1,598) 5,944
Net earnings, including noncontrolling interest 68,981 33,395
Net earnings (loss) attributable to noncontrolling interest (634) 0
Net earnings attributable to Bio-Techne 69,615 33,395
Other comprehensive income (loss):    
Foreign currency translation adjustments (8,646) 11,914
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8 1,682 2,143
Other comprehensive income (loss) (6,964) 14,057
Other comprehensive income (loss) attributable to noncontrolling interest (39) 0
Other comprehensive income (loss) attributable to Bio-Techne (6,925) 14,057
Comprehensive income attributable to Bio-Techne $ 62,690 $ 47,452
Earnings per share attributable to Bio-Techne:    
Basic (in dollars per share) $ 1.78 $ 0.87
Diluted (in dollars per share) $ 1.69 $ 0.83
Weighted average common shares outstanding:    
Basic (in shares) 39,094 38,536
Diluted (in shares) 41,158 40,025

Source